Tag: theranostics

Modulight Spotlights: LASER-SHARP RESEARCH – June 2025

Laser-sharp Research / Cancer therapy, fluorescence, in vitro, in vivo, laser-sharp research, liver cancer, ML7710, pancreas, pancreatic cancer, theranostics, University of Maryland

Chen-Hua Ma et al. Optical Therapeutics & Nanotechnology Laboratory at University of Maryland combined photoimmunotherapy with ethanol ablation to achieve improved drug retention and light penetration, especially important for treating pigmented organs like liver and pancreas. Modulight’s ML7710 laser was used for both therapeutic activation of the nanoconstruct, as well as for theranostic monitoring of the process.

Modulight Spotlights: LASER-SHARP RESEARCH – June 2025 Read More »

Synergizing photodynamic therapy and ethanol ablation: Light-activatable sustained-exposure ethanol injection technology for enhanced tumor ablation

Scientific papers / Cancer therapy, fluorescence, in vitro, in vivo, liver cancer, ML7710, pancreas, pancreatic cancer, theranostics, University of Maryland

Published in: Bioengineering & Translational Medicine Authors: Chen-Hua Ma, Jeffrey Yang, John A. Quinlan, Kathryn McNaughton, Michele L. Kaluzienski, Tessa Hauser, Matthew F. Starost, Jenna L. Mueller, Huang-Chiao Huang

Synergizing photodynamic therapy and ethanol ablation: Light-activatable sustained-exposure ethanol injection technology for enhanced tumor ablation Read More »

Modulight Spotlights: LASER-SHARP RESEARCH – July 2024

Laser-sharp Research / 672 nm, cancer, Cancer therapy, chemotherapy, Kill cancer, laser-sharp research, LaserSharpResearch, light activation, ML7710, prostate cancer, theranostics

New findings in prostate cancer research were reported by Xinning Wang and team at Case Western University, Comprehensive Cancer Center. Using ML7710 laser at 672 nm for activation of the drug, they were able to dramatically improve therapeutic effect in prostate cancer models.

Modulight Spotlights: LASER-SHARP RESEARCH – July 2024 Read More »